Pure Global AI
NCT06053658Not yet recruiting

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

M.D. Anderson Cancer CenterPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Renal Cell Carcinoma
Drug/Device/Intervention
Tivozanib
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
M.D. Anderson Cancer Center
Location
Houston, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Jan 31, 2024
End date
Nov 01, 2028
Enrollment
48 participants
Primary outcome

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Summary

To learn if giving tivozanib in combination with nivolumab can help to control advanced
 nccRCC.

ICD-10 classifications
Malignant neoplasm of kidney, except renal pelvisMalignant neoplasm of renal pelvisSecondary malignant neoplasm of kidney and renal pelvisBenign neoplasm: KidneyBenign neoplasm: Renal pelvis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06053658
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06053658 through Pure Global AI's free database. This Phase 2 trial is sponsored by M.D. Anderson Cancer Center and is currently Not yet recruiting. The study focuses on Renal Cell Carcinoma. Target enrollment is 48 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.